Outcomes of Mechanically Ventilated Patients with COVID-19 Associated Respiratory Failure

King, Christopher S.; Sahjwani, Dhwani; Brown, Alison; Feroz, Saad; Cameron, Paula C; Osborn, Erik; Desai, Mehul; Djurkovic, Svetolik; Kasarabada, Aditya; Hinerman, Rachel; Lantry, James; Shlobin, Oksana A.; Ahmad, Kareem; Khangoora, Vikramjit; Aryal, Shambhu; Collins, A.C.; Speir, Alan M.

doi:10.1101/2020.07.16.20155580

Cited by 23 publications

(26 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, 15% (n = 362) of COVID-19 and only 9% (n = 610) of Influenza cases required ventilation. This corresponds to recent studies on hospitalized patients with showing that between 12% and 17% of patients required MV (Karagiannidis et al, 2020;King et al, 2020;Richardson et al, 2020). The reported 9% of ventilated patients treated with ECMO is in line with published results and gives an estimate of ECMO treatment in patients with COVID-19 in Germany (Karagiannidis et al, 2020;King et al, 2020).…”

Section: Discussionsupporting

confidence: 90%

Clinical outcomes and characteristics of patients hospitalized for Influenza or COVID-19 in Germany

Ludwig

Jacob

Basedow

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Highlights Male sex and old age associated with poor outcome for both diseases. Overall, inhospital mortality is twofold higher for COVID-19 patients. Ventilation time is more than three times longer for COVID-19 than for Influenza. COVID-19 patients discharged after ventilation stayed in hospital twice as long. The proportion of patients with severe outcomes higher for COVID-19 than for Influenza.

show abstract

Section: Discussionsupporting

confidence: 90%

Clinical outcomes and characteristics of patients hospitalized for Influenza or COVID-19 in Germany

Ludwig

Jacob

Basedow

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…7% in mechanically ventilated patients 13. Death rate in a study conducted by Shukla et al mentions death rate of 3% in their study while death rate in our study was 6.9% 11.…”

contrasting

confidence: 44%

Profile of COVID-19 patients in COVID dedicated tertiary care centre in Himachal Pradesh: a prospective observational cross sectional study

Lal¹,

Bhawani²,

Dheer³

et al. 2021

Int J Res Med Sci

View full text Add to dashboard Cite

Background: COVID-19 pandemic originated in China in December 2019 and fumed in whole world over few months. Millions of deaths have occurred worldwide till now because of this pandemic. Causative agent was identified as severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) causing viral pneumonia and serious manifestations were seen in association with increased age and comorbidies.Methods: This study was planned in very initial stage of pandemic in our country to study the profile of COVID-19 patients. This study was conducted over a period of six months from April 2020 to September 2020 at SLBSGMCH, Mandi at Nerchowk.Results: 202 patients were enrolled for this study with mean age of presentation 48 years, 61 were females, 147 (72%) were senior citizens, most patients were from district Mandi and most common symptoms were fever (58%), cough (46%), shortness of breath (35%) and associated commonest comorbidities were hypertension (HTN) (29%) and diabetes (23%). Median neutrophil to lymphocyte ratio (NLR) was higher (5.47) in moderate to severe disease and associated with poor outcome. All the 11 patients who were put on support of ventilator, succumbed to death.Conclusions: Most common symptoms were fever, cough, shortness of breath and most common comorbidty was HTN. Comorbidity, increased age and higher NLR were risk factors for severity and poor outcome. More research is needed to save mankind from this pandemic as still no specific therapy is available against this virus.

show abstract

“…Patient data from LIVE-AIR were censored after 28 days following trial enrollment. This is noteworthy because patients with COVID-19 who are critically ill and/or who require IMV typically have extended time to recovery, sometimes beyond 28 days [21,47,48]. Therefore, the model may underestimate time to recovery for patients who require IMV by only allowing up to 28 days of hospital resource use.…”

Section: Discussionmentioning

confidence: 99%

Clinical Benefits and Budget Impact of Lenzilumab plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with COVID-19 in the United States from the Hospital Perspective

Kilcoyne¹,

Jordan²,

Zhou

et al. 2021

Preprint

View full text Add to dashboard Cite

Aims: The study estimated the clinical benefits and budget impact of lenzilumab plus standard of care (SOC) compared with SOC alone in the treatment of hospitalized COVID-19 patients from the United States hospital perspective. Materials and Methods: An economic model was developed to estimate the clinical benefits and costs for an average newly hospitalized COVID-19 patient, with a 28-day time horizon for the index hospitalization. Clinical outcomes from the LIVE-AIR trial included failure to achieve survival without ventilation (SWOV), mortality, time to recovery, intensive care unit (ICU) admission, and invasive mechanical ventilation (IMV) use. Base case costs included drug acquisition and administration for lenzilumab and hospital resource costs based on the level of care required. The inclusion of 1-year rehospitalization costs was examined in a scenario analysis. Results: In the base case and all scenarios, treatment with lenzilumab plus SOC improved all specified clinical outcomes over SOC alone. Adding lenzilumab to SOC was also estimated to result in cost savings of $3,190 per patient in a population aged <85 years with CRP <150 mg/L and receiving remdesivir (base case). Per-patient cost savings were also estimated in the following scenarios: 1) aged <85 years with CRP <150 mg/L, with or without remdesivir ($1,858); 2) Black and African American patients with CRP <150 mg/L ($13,154); and 3) Black and African American patients from the full population ($2,763). In the full mITT population, a budget impact of $4,952 was estimated. When adding rehospitalization costs to the index hospitalization, a total per-patient cost savings of $5,154 was estimated. Conclusions: The results highlight the clinical benefits for SWOV, ventilator use, time to recovery, mortality, time in ICU, and time on IMV, in addition to a favorable budget impact from the United States hospital perspective associated with adding lenzilumab to SOC for patients with COVID-19 pneumonia.

show abstract

Outcomes of Mechanically Ventilated Patients with COVID-19 Associated Respiratory Failure

Cited by 23 publications

References 6 publications

Clinical outcomes and characteristics of patients hospitalized for Influenza or COVID-19 in Germany

Clinical outcomes and characteristics of patients hospitalized for Influenza or COVID-19 in Germany

Profile of COVID-19 patients in COVID dedicated tertiary care centre in Himachal Pradesh: a prospective observational cross sectional study

Clinical Benefits and Budget Impact of Lenzilumab plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with COVID-19 in the United States from the Hospital Perspective

Contact Info

Product

Resources

About